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Background: Elderly people are at increased risk for severe influenza illness and constitute therefore a major
target-group for seasonal influenza vaccination in most industrialized countries. The aim of this study was to
estimate influenza vaccine effectiveness (VE) among individuals aged 60+ years over three seasons and to assess if
the screening method is a suitable tool to monitor influenza VE in this particular target-group in Germany.
Methods: We identified laboratory-confirmed influenza cases aged 60+ years through the national communicable
disease reporting system for seasons 2010/11, 2011/12 and 2012/13. Vaccination coverage (VC) data were retrieved
from a database of health insurance claims representing ~85% of the total German population. We applied the
screening method to calculate influenza subtype-specific VE and compared our results with VE estimates from other
observational studies in Europe.
Results: In total, 7,156 laboratory-confirmed influenza cases were included. VE against all influenza types ranged
between 49% (95% confidence interval [CI]: 39–56) in 2011/12 and 80% (95% CI: 76-83%) in 2010/11. In 2010/11
subtype-specific VE against influenza A(H1N1)pdm and B was 76% and 84%, respectively. In the following seasons,
VE against influenza A(H1N1)pdm, A(H3N2) and B was 87%, -9% , 74% (2011/12), and 74%, 39%, 73% (2012/13). VE
was higher among hospitalized compared to non-hospitalized influenza A cases. Seventeen observational studies
from Europe reporting subtype-specific VE among the elderly were identified for the respective seasons (all applying
the test-negative design) and showed comparable subtype-specific VE estimates.
Conclusions: According to our study, influenza vaccination provided moderate protection against laboratory-confirmed
influenza A(H1N1)pdm and B in individuals aged 60+ but no or only little protection against A(H3N2). Higher VE among
hospitalized cases might indicate higher protection against severe influenza disease. Based on the available data, the
screening method allowed us to assess subtype-specific VE in hospitalized and non-hospitalized elderly persons. Since
controlling for several important confounders was not possible, the applied method only provided crude VE estimates.
However, given the precise VC-data and the large number of cases, the screening method provided results being in
line with VE estimates from other observational studies in Europe that applied a different study design.
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Elderly people are at increased risk for severe influenza
disease or influenza-associated complications [1]. There-
fore, the World Health Organization (WHO) and National
Immunization Technical Advisory Groups (NITAGs) in
most industrialized countries recommend seasonal in-
fluenza vaccination for this particular at-risk group [2-5].
The European Union aims to achieve a vaccination co-
verage of >75% in this age-group to reduce influenza-
associated morbidity and mortality [6]. However, due to
progressive deterioration in both innate and adaptive
immune function, aging is associated with a reduced
immune response to influenza vaccines [7]. Although it
seems plausible that this also translates into reduced vac-
cine effectiveness (VE) in this age-group, there are still
conflicting conclusions drawn by authors in respect to in-
fluenza VE among the elderly [8]. While some authors
concluded that evidence on influenza VE in this age-group
is poor [8] or even lacking [9], others found – based on
results from post-marketing observational studies –
evidence for a substantial reduction in influenza-related
morbidity and mortality among the elderly [10].
To guide national immunization strategies and re-
search into the development of improved influenza vac-
cines, annual estimates of influenza VE in vaccination
target-groups are important [11]. In fact, suboptimal ef-
fectiveness of seasonal influenza vaccines has recently
led researchers and policy makers to advocate for better
vaccines [9,12]. Since VE varies not only by characteristics
of the vaccinees (e.g., age or underlying medical condi-
tions), but also by influenza season and subtype, many
countries have established annual assessments of influenza
VE. An increasingly applied method to assess influenza VE
is the test-negative design (TND) [13-17]. Patients with
medically attended acute respiratory illness (ARI) consti-
tute the study population, and participants are considered
as cases if they are tested positive for influenza and as
controls if tested negative in a specific time-period after
symptom onset [18,19]. In addition to the TND, the
screening method has been used to estimate seasonal and
pandemic VE in various settings [20-24]. This method
estimates VE by comparing vaccination coverage (VC) in
influenza-positive cases with VC in the population where
the cases derived from (e.g., the same age-group) [25]. If
representative data on influenza cases and influenza VC
are available, the screening method provides an inex-
pensive and ready-to-use method that can be useful in
providing early VE estimates [26] or in identifying changes
in VE over time when conducted repeatedly [14,20]. How-
ever, compared to TND the screening method seems more
prone to selection bias, and controlling for important con-
founders, such as comorbidities, might not be possible due
to lack of availability of these data [25]. Nonetheless, when
applying stratified analyses or limiting the analysis to amore homogeneous population (such as elderly persons)
the risk of bias can be reduced.
With this study we aimed to (i) estimate VE against
laboratory-confirmed influenza for the seasons 2010/11-
2012/13 among persons aged 60+ years, (ii) compare VE
in preventing hospitalized and non-hospitalized influenza,
and (iii) assess if the screening methods is a suitable tool
for the monitoring of influenza VE among the elderly
in Germany.
Methods
Database for determining population vaccination
coverage
The source for seasonal influenza VC was the central
database of health insurance claims of the Associations
of Statutory Health Insurance Physicians (ASHIPs) in
Germany. ASHIPs administrative regions are identical to
the geographic regions of the 16 federal states, except
for one federal state that is divided into two ASHIP re-
gions. ASHIPs regularly receive claims data from all
ASHIP-associated physicians for ambulatory services,
covering more than 85% of the total population in
Germany. Within the ASHIP vaccination monitoring
project, anonymous data of ASHIPs are transferred to
the Robert Koch Institute (RKI) on a quarterly basis and
include information on age (month/year), date of patient
contact, as well as date and type of vaccination [27]. We
extracted information on seasonal influenza vaccination
for seasons 2010/11, 2011/12 and 2012/13 among all in-
dividuals aged 60+ years and calculated VC for the total
elderly population and by age-strata. Data were available
from 16 of the 17 ASHIP regions.
Identification of influenza cases
In Germany, laboratory-confirmed influenza infections
are notifiable according to the German Protection
against Infection Act since 2001 [28]. We identified in-
fluenza cases through the national communicable dis-
ease reporting system. Within this system, case-based
data of patients with laboratory-confirmed influenza in-
fection are collected by local public health authorities
and transmitted electronically via state health depart-
ments to RKI. Cases reports include information on age
(month/year), place of residence, date of disease onset,
date of notification, receipt of influenza vaccine, labora-
tory confirmation of disease, influenza type and subtype,
and hospitalization. Additional information, such as type
or name of the influenza vaccine is rarely reported and
information on comorbidities is almost never provided.
For our analysis, notified cases aged 60 years and older
were included if infection was laboratory-confirmed (i.e.,
detection of influenza antigens using enzyme immuno-
assays, polymerase chain reaction, or virus culture), and
if information on cases’ vaccination status was available.
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nated in this current season” in the electronic surveillance
system. An exact date of vaccination was provided for
66% of all vaccinated influenza cases between 2010/11-
2012/13, of whom only 9 had a symptom onset <14 days
post vaccination. These cases were considered as “non-
vaccinated”. For the remaining 34% of vaccinated cases,
for whom the date of vaccination was missing, the num-
ber of persons with disease onset within 14 days after vac-
cination was regarded as unlikely. Since this assumption
can potentially increase the numbers of vaccine failures
and decrease VE thereby, we conducted a sensitivity ana-
lysis by excluding people from the analysis who were vac-
cinated <14 days prior to symptom onset (results are
presented in Additional file 1: Table S1). For each season,
proportion of laboratory confirmed influenza cases vacci-
nated with 95% CIs stratified by age-group (60+, 60–69,
70–79, 80+ years), influenza subtype and hospitalization
status (yes/no) were calculated.
The data on influenza cases reported under the German
Protection against Infection Act are freely available from
the national surveillance database at https://survstat.rki.de.
Definition of influenza seasons
We included cases with disease onset during the study
period that was defined from week 40 of the previous to
week 20 of the following year for each of the three sea-
sons under investigation. In a sensitivity analysis, we re-
stricted VE calculation to cases with disease onset
during the respective influenza season as defined by
RKI’s Working Group for Influenza. According to the
Working Group, which collects syndromic and labora-
tory data within a sentinel system of primary care physi-
cians in Germany, influenza seasons were defined from
weeks 50/2010-14/2011, 6/2012-16/2012 and 50/2012-
16/2013, respectively [29,30].
Statistical analysis
We used descriptive analysis for seasonal influenza VC.
In brief, VCs and 95% CIs were calculated as proportion
of patients having received claimed influenza vaccina-
tions among the total statutory health insured popula-
tion by region, age-group, and season.
Calculation of vaccine effectiveness (VE)
VE and 95% CIs were calculated using the screening
method according to Farrington [25] with the follo-
wing formula:
VE ¼ PV −PCV
PV 1−PCVð Þ
where PV is the proportion population vaccinated (i.e.
VC) in the respective age-group and where PCV isthe proportion of cases vaccinated. We calculated VE
by season, age-group, hospitalization status, and in-
fluenza subtype.
Identification of factors associated with vaccine failure
We defined vaccine failure as a laboratory-confirmed influ-
enza infection in a person vaccinated against influenza in
the respective season. To examine independent predictors
of breakthrough infections (leading to vaccine failure) for
each influenza season and by influenza subtype, we used a
logistic regression model including potential confounding
factors (age, sex, hospitalization, week since start of influ-
enza season) and calculated odds ratios (OR) and 95% CI.
Two-sided hypothesis tests were performed and a p-value
of ≤0.05 was considered statistically significant. The statis-
tical software package STATA®, version 11 (STATA Corp.,
College Station, TX, USA) was used.
Identification of observational VE studies from Europe
To compare our study results with influenza VE estimates
among the elderly in other observational studies in Europe,
we conducted a systematic literature search in PubMed
using the following search strategy: (((influenza) AND
vaccine) AND effectiveness) AND Europe (restrictions:
publication year 2010 to 2015; language: English; species:
human). Date of last search was 17 February 2015. In ad-
dition, we complemented our search strategy by comparing
identified studies with those identified by a recently pub-
lished meta-analysis by Darvishian et al. [31]. Only studies
were included that reported subtype-specific VE estimates
in at least one of the seasons 2010/11-2012/13. We ex-
tracted (subtype-specific) VE estimates and compared
these results with ours. We excluded studies which used
other designs than the TND and studies providing “early”,
“mid-season”, or “interim estimates”.
Ethical considerations and data protection
Since we analyzed (i) anonymous VC-data from ASHIP
and (ii) anonymous data on influenza cases that are col-
lected routinely within the German surveillance system
for notifiable diseases, ethical approval was not obtained.
The Federal Commissioner for Data Protection and
Freedom of Information in Germany has approved the
ASHIP vaccination monitoring project.
Standards of reporting
We followed the STROBE guidelines in reporting this
study [32].
Results
Influenza vaccination coverage among the elderly
2010/11-2012/13
VC by age-group and season is shown in Table 1. Over
the three seasons, VC decreased slightly in all age-
Table 1 Seasonal influenza vaccination coverage by age
group estimated from health insurance claims data,










≥18 years 21.0 19.8 17.4
≥60 years 44.0 42.1 37.4
60-69 years 35.9 33.0 28.2
70-79 years 48.3 46.7 42.1
≥80 years 51.4 50.6 45.6
*Upper and lower bounds of the 95% CIs were 0.2% points above or below
the point estimates and are not shown in the tables.
Table 2 Characteristics of laboratory-confirmed influenza








Total 1,174 (100) 767 (100) 5,217 (100)
Cases vaccinated 162 (14.0) 208 (27.1) 921 (17.7)
Influenza subtypes
Influenza type A 774 (65.9) 537 (70.0) 3,069 (58.8)
Influenza type B 251 (21.4) 97 (12.7) 1,267 (24.3)
Influenza A/B1 137 (11.7) 89 (11.6) 806 (15.5)
No data 12 (1.0) 44 (5.8) 75 (1.4)
Influenza strains
A(H1N1)pdm 582 (49.6) 12 (1.6) 859 (16.5)
A(H3N2) 1 (0.1) 118 (15.4) 168 (3.2)
B 251 (21.4) 97 (12.7) 1267 (24.3)
Not genotyped 137 (11.7) 89 (11.6) 806 (15.5)
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based on data from an average 18 million (i.e. ~85% of
the total 22 million) individuals of this age-group living
in Germany. VC in this age-group ranged between 37%
and 44% and increased with age (Table 1).Missing data on strains 203 (17.3) 451 (58.8) 2117 (40.6)
Men (%) 589 (50.2) 306 (40.0) 2440 (46.8)
Age in years (mean ± SD) 67.2 (±6.9) 74.7 (±9.9) 71.2 (±8.9)
Age-group (years)
60-69 797 (67.9) 263 (34.3) 2485 (47.6)
70-79 307 (26.2) 267 (34.8) 1736 (33.3)
≥80 70 (6.0) 237 (30.9) 996 (19.1)
Hospitalization status
Hospitalized 455 (38.8) 317 (41.5) 2060 (39.5)
Not hospitalized 709 (60.4) 446 (58.5) 3087 (59.2)
Data may not add up to 100% due to missing data.
1Reported as influenza, type A/B, not specified.Notified influenza cases aged ≥60 years, 2010/11-2012/13
In total 1,371 (2010/11), 1,034 (2011/12) and 6,803
(2012/13) laboratory-confirmed influenza cases aged 60+
were notified to the RKI during the study period, re-
spectively. The high number of laboratory-confirmed
cases in the season 2012/13 reflected the severity of the
influenza wave in this particular season in Germany
[29]. Among all notified cases, information on laboratory
confirmation was available in more than 96%, and infor-
mation on vaccination status was available in more than
75%. In the final analysis we included 1,174 (85.6%)
cases in the season 2010/11, 767 (74.1%) cases in the
season 2011/12, and 5,217 (76.7%) cases in the season
2012/13, respectively. In two seasons (2011/12 and
2012/13), excluded cases were older than included cases
and in the season 2012/13, excluded cases were more
likely to be hospitalized (40% vs 44%, p = 0.01; for details
see online Additional file 1: Table S2).Characteristics of included influenza cases aged ≥60 years
Characteristics of included influenza cases are shown in
Table 2. Proportions of cases vaccinated ranged from
14% in season 2010/11 to 27% in season 2011/12. In two
seasons (2010/11 and 2012/13), subtype A(H1N1)pdm
was the dominant influenza A virus. The season 2011/12
was dominated by subtype A(H3N2).
Overall, for 66.2% of cases information on the date of
vaccination was available. Among these vaccinated cases,
only four (2.4%), one (0.5%) and four (0.4%) in the season
2010/11, 2011/12 and 2012/13, respectively, were consid-
ered as non-vaccinated, since onset of disease occurred
within 14 days after vaccination. Excluding these nine
cases from analysis did not affect VE estimates (for detailssee online Additional file 1: Table S1). Approximately 40%
of cases were notified as hospitalized in each season.
Vaccine effectiveness
Table 3 provides data on VE estimates in individuals
aged 60+ stratified by influenza subtypes, age-group and
hospitalization status for all seasons. In the season 2010/
11, VE was 76% (95% CI, 70-81%) for the predominantly
circulating influenza A(H1N1)pdm and 84% (95% CI,
76-90%) for influenza B. VE increased with age for both
subtypes and were higher in hospitalized compared to non-
hospitalized patients. In the season 2011/12, VE was 87%
(95% CI, 14-100%) for A(H1N1)pdm, −9% (95% CI, −59-
26%) for influenza A(H3N2) and 74% (95% CI, 55-86%) for
influenza B. VE estimates against influenza A(H3N2) de-
creased with age, and were higher among hospitalized
compared to non-hospitalized cases. However, a sta-
tistically significant protective effect against laboratory
confirmed A(H3N2) infection was not observed. In the
season 2012/13, VE was 74% (95% CI, 69–79) for in-
fluenza A(H1N1)pdm, 39% (95% CI, 13-58%) for influenza
Table 3 Vaccine effectiveness (VE in %) against laboratory-confirmed influenza stratified by influenza-subtype,
age-groups and hospitalization status, season 2010/11-2012/13, Germany
Age-group (years) Season 2010/11 Season 2011/2012 Season 2012/2013
VE against influenza (all types) n = 1,174 n = 767 n = 5,217
60-69 72 (65–77) 59 (43–71) 65 (61–69)
70-79 82 (75–87) 56 (43–67) 63 (58–67)
≥80 86 (71–94) 40 (22–55) 60 (54–66)
≥60 80 (76–83) 49 (39–57) 64 (63–67)
≥60 non-hospitalized 77 (72–81)1 37 (22–49)2 63 (59–66)1
≥60 hospitalized 83 (78–88)1 62 (51–72)2 67 (63–71)1
VE against influenza A n = 774 n = 537 n = 3,069
60-79 75 (69–80) 55 (43–65) 62 (58–66)
≥80 86 (64–96) 36 (11–54) 54 (44–62)
≥60 77 (72–81) 46 (35–56) 60 (57–64)
≥60 non-hospitalized 72 (64–79)2 32 (14–47)2 57 (52–62)2
≥60 hospitalized 82 (75–88)2 63 (49–74)2 66 (61–71)2
VE against influenza A (H1N1)pdm n = 582 n = 12 n = 859
60-79 74 (67–79) 85 (−6-100) 74 (68–79)
≥80 91 (63–99) NA3 64 (39–80)
≥60 76 (70–81) 87 (14–100) 74 (69–79)
≥60 non-hospitalized 68 (58–76)2 NA3 70 (62–77)1
≥60 hospitalized 83 (76–89)2 NA3 80 (72–86)1
VE against influenza A (H3N2) n = 1 n = 118 n = 168
60-79 NA3 33 (−16-63) 47 (18–66)
≥80 NA3 −49 (−171-17) 22 (−49-60)
≥60 NA3 −9 (−59-26) 39 (13–58)
≥60 non-hospitalized NA3 −48 (−132-5)2 27 (−8-51)2
≥60 hospitalized NA3 56 (−1-83)2 73 (30–92)2
VE against influenza B n = 251 n = 97 n = 1,267
60-79 83 (74–89) 73 (49–86) 74 (69–79)
≥80 89 (55–99) 80 (8–98) 66 (52–75)
≥60 84 (76–90) 73 (54–85) 73 (68–77)
≥60 non-hospitalized 82 (72–89)1 73 (42–89)1 75 (69–80)1
≥60 hospitalized 87 (73–95)1 72 (39–89)1 69 (61–77)1
1Not-hospitalized vs. hospitalized statistically not significant (p > 0.05).
2Not-hospitalized vs. hospitalized statistically significant (p ≤ 0.05).
3No/low number of cases.
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this season, VE estimates against influenza A(H3N2) de-
creased with age and showed no protective effect in indi-
viduals aged 80 and older and among non-hospitalized
cases. For the sensitivity analysis, in total 1,168 (99.4%),
664 (86.6%) and 5,182 (99.3%) cases were included when
applying a narrower definition for the influenza seasons.
In none of the seasons did VE estimates differed by more
than 3% from those calculated in the primary analysis
(data not shown). Further sensitivity analyses, e.g., assu-
ming that influenza vaccination coverage (VC) among ex-
cluded cases was 50% or 200% of VC among includedcases, or assuming that 50% of cases with missing in-
formation on the exact date of vaccination were regarded
as non-vaccinated are shown in the online supplement
(Additional file 1: Tables S3–S5).
Factors associated with vaccine failure
In all three seasons, factors independently associated
with vaccine failure were identified among influenza A
cases only (Table 4). The odds for a breakthrough dis-
ease increased with age (p ≤0.05 for all three seasons). In
addition, in all seasons vaccine failures was significantly
less common among hospitalized compared to non-
Table 4 Factors independently associated with seasonal influenza vaccine failures among cases aged 60 years and
older, Germany, seasons 2010/11-2012/13
Season Influenza-type Variable/Category Adjusted OR (95% CI) p-value
2010/11 A(H1N1) Age in years 1.03 (1.00-1.07) 0.04
Weeks since begin influenza season1 1.02 (0.94-1.11) 0.672
Hospitalization 0.45 (0.28-0.73) <0.01
2011/12 A(H3N2) Age in years 1.07 (1.03-1.12) <0.01
Weeks since begin influenza season1 1.12 (1.01-1.26) 0.03
Hospitalization 0.23 (0.09-0.62) <0.01
2012/13 A(H1N1) Age in years 1.05 (1.02-1.08) <0.01
Weeks since begin influenza season1 1.02 (0.95-1.11) 0.492
Hospitalization 0.51 (0.33-0.80) <0.01
A(H3N2) Age in years 1.06 (1.02-1.11) <0.01
Weeks since begin influenza season1 1.11 (0.98-1.26) 0.082
Hospitalization 0.35 (0.12-1.00) 0.05
OR, Odds ratio; 95% CI, 95% confidence interval; ns, not statistically significant.
1Influenza season defined as from week 40 of the previous year to week 20 in the following year.
2Removing this (non-significant) variable did not influence the final model.
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period since start of the influenza season increased the
odds of a A(H3N2) breakthrough infection, but only in
the season 2011/12.Comparison of study results with results from other
observational studies
Our literature search yielded 141 records in PubMed. Of
twenty-two potentially relevant studies, 15 met the in-
clusion criteria and an additional 2 studies [33,34] were
identified through the meta-analysis of Darvishian et al.
Finally, data from 17 studies provided enough data and
were extracted (seven in 2010/11, four in 2011/12, and
six in 2012/13) [17,33-48]. In all seasons and for all
influenza-subtypes, VE estimates from our study were
close or within the 95% CI of almost all identified TND
studies (Table 5). Of particular interest, the included
studies did not identify a protective effect against
laboratory-confirmed influenza A(H3N2) infection in
the 2011/12 season [39,41,49] and no or low VE for the
2012/13 season [35,37,44], similar to what we have ob-
served in our analysis.Discussion
In this study we were able to show that among the
elderly VE against influenza A(H1N1)pdm and B was
moderate in all three seasons 2010/11-2012/13, whereas
VE against influenza A(H3N2) was low in two consecu-
tive seasons. These VE estimates were comparable to re-
sults provided by other observational studies in Europe
that used the TND, suggesting that the screening
method can be a suitable tool to generate useful in-
fluenza VE estimates at least for this particular age-group.In studies applying the TND, patients with medically
attended acute respiratory illness are recruited into the
study and –if performed in an appropriate way- systema-
tically tested for influenza virus. Those with laboratory-
confirmed influenza infection are defined as cases and
otherwise as controls. Since both groups are recruited in
one process and both derived from the same population
the TND has been found to be less susceptible to bias
[19]. In the absence of RCTs, the TND has been advocated
as a valid method to calculate almost unbiased influenza
VE estimates [18,50] under a wide range of assumptions
[51]. As with all observational studies adjusting for im-
portant confounders has still to be performed [18]. How-
ever, in particular for the age-group 60+ there are often
only small differences between crude and adjusted point
estimates as shown in most of the observational studies
identified in our study [17,35,38,40,43].
The screening method has been described as a rapid
and cheap tool to survey vaccine effectiveness, parti-
cularly when denominator data on individuals are not
available [25,26]. For the screening method, only a ran-
dom sample of cases is needed. However, accurate and
age-group specific VC rates are crucial to produce valid
VE estimates [25,52]. In our study, the random sample
derived from the national communicable disease re-
porting system. Although this system collects data on
laboratory-confirmed influenza infections nationwide,
selection bias (e.g., enhanced testing for influenza among
chronically ill patients), observer bias (e.g., vaccinated
cases are less likely to be swabbed for influenza) or
reporting bias (e.g., differences in notification behavior
among physicians) cannot completely be ruled out. In
addition, data on important confounders are not syste-
matically reported in the system and adjusting for these
Table 5 Vaccine effectiveness (VE) against influenza subtypes among the elderly: comparison of results from this
present study with results from observational studies in Europe using the test-negative design, seasons
2010/11-2012/13






(Years) VE-analysis A(H1N1)pdm A(H3N2) B
Season 2010/11
This study ≥60 Crude 76 (70–81) - 84 (76–90)
Adjusted - - -
Europe (I-MOVE)1 [38] ≥60 Crude 73 (48–86) - 48 (−2-73)
Adjusted 72 (27–90) - 56 (−38-86)
UK [42] ≥65 Crude - - -
Adjusted 70 (0–85)2 - 65 (20–80)2
Spain I [40] ≥50 Crude 67 (27–85)3 - -
Adjusted 69 (0–91)3 - -
Spain II [43] ≥60 Crude 60 (20–80)4 - -
Adjusted 59 (16–76)4 - -
Spain III [45] ≥65 Crude 41 (−36-74)5 - -
Adjusted - - -
Spain IV [46] ≥65 Crude 54 (−18-82)6
Adjusted -
Germany [17] ≥60 Crude 89 (1–99)3 - -
Adjusted 92 (−67-100)3 - -
Season 2011/12
This study ≥60 Crude 87 (14–100) −9 (−59-26) 74 (55–86)
Adjusted - - -
Europe (I-MOVE)1 [39] ≥60 Crude - 6 (−41-38) -
Adjusted - 15 (−33-46) -
UK [41] ≥65 Crude - - -
Adjusted - 48 (−50-82) -
Spain I [49] ≥65 Crude - 4 (−106-55)7 -
Adjusted - 19 (−146-73)7 -
Spain II8 [47] ≥65 Crude - 26 (−69-78) -
Adjusted - - -
Season 2012/13
This study ≥60 Crude 74 (69–79) 39 (13–58) 73 (68–77)
Adjusted - - -
Europe (I-MOVE)1 [37] ≥60 Crude 59 (14–80) 37 (−13-65) 44 (9–66)
Adjusted - - -
UK [44] ≥65 Crude - - -
Adjusted −14 (−206-57) 65 (18–85)
Denmark [35] ≥65 Crude - −19 (−52-6) 64 (17–84)
Adjusted - −11 (−41-14) 69 (26–87)
Lithuania8 [48] ≥60 Crude 92 (−55-100)9
Adjusted -
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Table 5 Vaccine effectiveness (VE) against influenza subtypes among the elderly: comparison of results from this
present study with results from observational studies in Europe using the test-negative design, seasons
2010/11-2012/13 (Continued)
Portugal8 [33] ≥60 Crude 80 (19–95)10 - -
Adjusted - - -
Multicenter11 [34] ≥65 Crude12 34 (−22-64) 46 (−16-75) 46 (23–63)
Adjusted 13 (−68-55) 39 (−40-73) 41 (12–61)
VE, vaccine effectiveness.
§VE point estimates were rounded off to whole numbers.
1I-MOVE pooled data from other European countries; therefore, overlapping with some of the individual studies from the same season is likely.
2approx. VE since data for this age group were presented as figures only.
3VE against all influenza types; >80% of all subtypes identified were H1N1.
4VE against all-type influenza hospitalization; 76% of all subtypes identified were H1N1.
5VE against all-type hospitalization; 95% of all subtypes identified were H1N1.
6VE against all influenza types; 56% of all subtypes identified were H1N1, 41% were B.
7VE against all influenza cases; 92% of all subtypes identified were H3N2.
8Data extracted from the study of Darvishian et al. [31].
9VE against all influenza types; distribution among the whole study population: 41% H1N1, 40% B, 19% H3N2.
10VE against all influenza types; distribution among the whole study population: 53% H1N1, 43% B.
11VE against hospitalization; data collected in Spain, France and in the Russian Federation.
12adjusted for study site.
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duced the impact of these shortcomings since we calcu-
lated VE for small age strata among elderly patients, for
whom annual influenza vaccination is generally re-
commended in Germany. Since our results were rather
similar to those from studies using the TND, it can be
hypothesized that in this particular age-group adjust-
ment for underlying medical conditions might not play
such an important role. Furthermore, age-group specific
VC rates were calculated in our study from a large data-
base of health insurance claims covering the majority of
the German population. The database has been shown
to be a valid and representative instrument to describe
VC in various age-groups in Germany [27,53] - a pre-
requisite for valid VE estimates when the screening
method is applied [25].
Due to the large sample size we were able to assess
subtype-specific VE even in different age-strata within
the elderly population. In contrast, in observational
studies using the TND estimation of strain-specific VE
in the elderly is often not possible or limited by large
CIs [17,35,36,42,54]. Furthermore, the assessment of VE
against severe influenza using the TND is possible but
would require additional study sites in hospitals and is
often logistically challenging and resource-demanding.
In view of these strengths and limitations, the screening
method can be regarded as an useful method for the
rapid assessment of crude influenza VE in the elderly
when data on laboratory-confirmed influenza cases are
available.
In our study, one of the major findings was that VE
against influenza A(H3N2) was low in two consecutive
seasons. This finding confirms the results from previous
studies where no or only little protective effect against
influenza A(H3N2) was observed [35,37,39,41,44,49].Since antigenetic changes of the A/Victoria/361/2011
(H3N2)-like vaccine during the manufacturing process
has been reported, the WHO has recommended that the
influenza A(H3N2) vaccine component for use in the
2013/14 season should be updated [55].
In addition to older age, the probability of vaccine fail-
ure increased over time during season 2011/12 among
cases infected with influenza A(H3N2). The same effect
has been observed in other settings and it was discussed
that this may be due to virus changes or waning im-
munity after vaccination [39,41,49]. Due to the higher
mutation rate of influenza A compared to B viruses [56]
it is plausible that these effects are mainly identified
among patients infected with influenza A.
Interestingly, we found that vaccine failure was nega-
tively associated with hospitalization. This was true in all
seasons among cases infected with influenza A viruses.
A recently conducted study in Spain suggested that VE
may be greater in preventing severe than in preventing
mild cases, and that the benefits of vaccination may be
greater than suggested [57]. However, in our study we
cannot fully exclude that this effect was due to bias, e.g.
the healthy vaccinee effect or different testing behavior
for influenza in vaccinated inpatients and vaccinated out-
patients. Further studies exploring these potential VE dif-
ferences by clinical outcome would be important to better
estimate the true effect of influenza vaccination in pre-
venting severe influenza and influenza-related mortality.
Strengths and limitations
Our study benefits from its large sample size. During
three consecutive influenza seasons we were able to in-
clude more than 7,000 laboratory-confirmed influenza
cases aged 60+ both from the outpatient and inpatient
sector. Due to this large size we were able to assess
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In addition, since we used age-specific VC data for each
single season derived from a large database representing
~85% of the German population, VC can be regarded as
representative. Finally, by limiting the studies to individ-
uals aged 60+ we were probably able to reduce the risk
of biases to at least some extent, which was reflected by
similar VE estimates when comparing to studies using
the TND.
However, some limitations have to be acknowledged.
First, cases were identified by the mandatory disease sur-
veillance system and the quality of our analysis depends
on the quality of the reported data transmitted to the
RKI. Since only laboratory-confirmed infections are noti-
fiable in Germany and since it is the decision of the
physician whether or not to swab patients for influenza,
we cannot exclude that vaccinated persons were less
likely be tested for influenza virus infection, which might
have led to an overestimation of VE. However, this
would not explain differences in VE between hospital-
ized and non-hospitalized cases. Second, cases were de-
fined as vaccinated if they were notified as “currently
vaccinated” and considered as non-vaccinated if disease
onset occurred within 14 days after vaccination. Since
date of vaccination was provided by 66% of all cases
only, it is possible that in cases with unknown vaccin-
ation date disease occurred within 14 days after receipt
of the vaccine leading to an underestimation of VE.
However, since the proportion among cases with infor-
mation on vaccination date with disease onset prior
14 days after receipt of vaccine was less than 1%, it
seems rather unlikely that this proportion was signifi-
cantly higher among those without information on vac-
cination date. Third, we were not able to control for
some important confounders such as comorbidities, but
limiting our study population to persons aged 60+ might
have accounted for this. Fourth, although >85% of all
cases were laboratory confirmed using PCR or cell-
culture, subtyping was only performed in 70% of cases.
Finally, since vaccine types are not reported systematic-
ally for notified influenza cases, vaccine type or product
specific VE cannot be calculated. Overall, optimizing the
completeness of the data regarding hospitalization sta-
tus, vaccination status, and date of vaccination as well as
additional information on comorbidities could improve
the validity of our VE estimates.
Conclusions
In conclusion, the screening method can be used to
rapidly assess influenza subtype-specific VE among the
elderly in Germany. Due to high numbers of cases, VE can
be estimated even for rather narrow age-ranges and non-
dominating influenza subtypes within the elderly popu-
lation as well as for hospitalized and non-hospitalizedpatients. Since adjusting for important confounders and
the assessment of product-specific VE is not possible,
the screening method can be regarded as an important
but only supplementary tool for assessing crude VE,
in addition to more precise but also more resource-
demanding TND-studies for the post-marketing evaluation
of influenza vaccines.
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